Accessibility Menu
Ligand Pharmaceuticals logo

Ligand Pharmaceuticals

(NASDAQ) LGND

Current Price$300.09
Market Cap$5.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1994)+921%
5 Year+329%
1 Year+129%
1 Month+16%
Ligand Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 296.452026-07-16
Ligand Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8.11%USD 322.612026-07-09
1 month+16.14%USD 255.252026-06-16
3 month+27.88%USD 231.822026-04-17
Year to date+56.79%USD 189.072025-12-31
1 year+128.69%USD 129.632025-07-16
3 year+331.14%USD 68.762023-07-17
5 year+329.49%USD 69.022021-07-16
Since inception+921.21%USD 29.031994-11-25

Ligand Pharmaceuticals Financials at a Glance

Market Cap

$5.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$274.48M

Net Income (TTM)

$153.56M

EPS (TTM)

$7.38

P/E Ratio

40.19

Dividend

$0.00

Beta (Volatility)

1.05 (Average)

Price

$300.09

Volume

1,106

Open

$295.71

Previous Close

$296.45

Daily Range

$292.41 - $300.55

52-Week Range

$129.55 - $326.63

Estimated Earnings Date

Aug 6, 2026

LGND News

SellAlert-Purple.png

Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?

Seena HassounaJun 14, 2026
SellAlert-Red.png

A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million

Cory RenauerJun 7, 2026
SellAlert-Blue.png

CLO Sells LGND 5,000 Shares for $1.0 Million

Seena HassounaMar 30, 2026
SellAlert-Blue.png

Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know

Jonathan PoncianoMar 27, 2026
SellAlert-Green.png

This Fund Sold $9 Million of Ligand Stock After an 84% Rally — What Investors Should Know

Jonathan PoncianoNov 17, 2025
Foolcom-Featured.png

Ligand (LGND) Q2 Revenue Jumps 15%

Motley Fool Markets TeamAug 7, 2025
GettyImages-1159345748

Ligand's Revenue Soars in Q1 Thanks to Gilead's COVID Drug

Keith SpeightsMay 4, 2021
GettyImages-897880260

3 Signs the Ligand Short Squeeze Is Over

Jason HawthorneApr 22, 2021
Page 1

LGND: Motley Fool Moneyball Superscore

77

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ligand Pharmaceuticals

Ligand helps big drug makers create and sell new medicines. It invests in medical research to earn money from future product sales. This model lets the company support many different treatments without building its own factories.

The Product Portfolio

  • Royalties: Monthly or quarterly payments earned from 12 major commercial drugs and over 100 development programs.
  • Captisol Technology: Special chemical tool that helps drugs dissolve better in the body so they can work effectively.
  • NITRICIL Platform: Technology using nitric oxide to treat skin conditions and other infections; currently used in the approved gel Zelsuvmi.
  • Material Sales: Revenue from selling the physical Captisol used by partners in their specific drug formulations.

Strategic Moves and Deals

  • Acquired Apeiron Biologics AG in July 2024 to gain rights to the cancer drug Qarziba.
  • Invested $50 million in Castle Creek Biosciences in February 2025 to support gene therapy research.
  • Backed Orchestra BioMed Holdings with $25 million in July 2025 for new heart health technologies.
  • Combined its Pelthos Therapeutics business with Channel Therapeutics in July 2025 to launch a skin treatment.
  • Bought rights from Arecor Limited in September 2025 to expand its biosimilar and technology access fees.

What Makes the Company Different?

Ligand operates with a very small team of 68 employees to manage a massive portfolio of medical assets. This lean structure focuses on high-margin royalty streams rather than the high costs of running clinical trials.

The Recent Financial Scorecard

  • Revenue reached $59.7 million in Q4 2025, up 39.4% from Q4 2024.
  • Net income hit $44.8 million in Q4 2025, compared to a loss of $31.1 million in Q4 2024.
  • Free cash flow grew to $45.8 million in Q4 2025, an increase of 65.1% year-over-year.
  • Operating income rose to $20 million in Q4 2025, up 307.9% from the previous year.

Final Evolution Summary

Ligand has shifted from a traditional biotech firm to a specialized investment company focused on medical royalties. By shedding heavy infrastructure and focusing on strategic capital, it has built a diverse stream of income from global medicine sales.

AI Generated • Apr 24, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

47

CEO

Todd Christopher Davis, MBA

Website

www.ligand.com

Headquarters

Jupiter, FL 94608, US

LGND Financials

Key Financial Metrics (TTM)

Gross Margin

98.61%

Operating Margin

36.72%

Net Income Margin

55.95%

Return on Equity

16.19%

Return on Capital

3.21%

Return on Assets

10.02%

Earnings Yield

2.49%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

20.04M

Volume

1.11K

Avg. Volume

334.75K

Financials (TTM)

Gross Profit

$270.66M

Operating Income

$100.78M

EBITDA

$222.24M

Operating Cash Flow

$123.42M

Capital Expenditure

-$466.00K

Free Cash Flow

$122.96M

Cash & ST Invst.

$779.41M

Total Debt

$451.98M

Ligand Pharmaceuticals Performance Analysis

Ligand Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 196,245,000-18.8%
20232023-12-31USD 131,314,000-33.1%
20242024-12-31USD 167,133,00027.3%
20252025-12-31USD 268,087,00060.4%
Ligand Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-305.1%
Q32025-09-30142.4%
Q42025-12-31-48.3%
Q12026-03-31-13.3%
Ligand Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.98N/A
20232023-12-31USD 2.94N/A
20242024-12-31USD -0.22N/A
20252025-12-31USD 6.13N/A
Ligand Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30110.9%
Q32025-09-302266.7%
Q42025-12-31-62.7%
Q12026-03-31-131.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$51.72M

+14.1%

Gross Profit

$49.65M

+22.6%

Gross Margin

95.99%

N/A

Market Cap

$5.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$126.41M

N/A

Employees

47

N/A

Net Income

-$13.35M

+68.6%

EBITDA

-$14.30M

+64.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$779.41M

+273.1%

Total Debt

$451.98M

+10061.4%

Accounts Receivable

$54.80M

+27.9%

Inventory

$13.27M

+12.3%

Long Term Debt

$450.89M

+12547.7%

Short Term Debt

$1.09M

+23.2%

Return on Assets

10.02%

N/A

Return on Invested Capital

6.76%

N/A

Free Cash Flow

$48.46M

+288.4%

Operating Cash Flow

$48.69M

+290.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MIRMMirum Pharmaceuticals, Inc.
$119.44+1.77%
BLTEBelite Bio, Inc
$149.90-0.51%
PRAXPraxis Precision Medicines, Inc.
$321.60+4.35%
ACADACADIA Pharmaceuticals Inc.
$25.55-0.31%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$68.12-0.04%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$28.53+0.04%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$42.41+0.04%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.44-0.05%

Questions About LGND

What is the current price of Ligand Pharmaceuticals?

Ligand Pharmaceuticals is trading at $300.09 per share.

What is the 52-week range for Ligand Pharmaceuticals?

Over the past 52 weeks, Ligand Pharmaceuticals has traded between $129.55 and $326.63.

How much debt does Ligand Pharmaceuticals have?

As of the most recent reporting period, Ligand Pharmaceuticals reported total debt of $451.98M.

How much cash does Ligand Pharmaceuticals have on hand?

Ligand Pharmaceuticals reported $115.09M in cash and cash equivalents in its most recent financial results.

What is Ligand Pharmaceuticals’s dividend yield?

Ligand Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services